Market News Archives

Cantor Fitzgerald Analyst Report Highlights Eupraxia’s Market Potential Post Successful Funding – ( $EPRX $IBB $XBI )

by Vista Partners LLC October 1, 2025 583Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) has catapulted into the biotech spotlight following an influential analyst report from Cantor Fitzgerald that reaffirmed its “Overweight” rating and set a robust $11 price target—nearly double the recent public offering price. This endorsement comes on the heels…

Eupraxia’s Diffusphere Tech Driving Growth And Interest: EOE Clinical Milestone and Big Public Offering

by John F. Heerdink, Jr. September 30, 2025 496Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) reported robust clinical results in its highest-dose cohort—8mg per injection—within the ongoing RESOLVE Phase 2b trial for patients with eosinophilic esophagitis (EoE). The pronounced tissue health improvements and eosinophil reduction in Cohort 9 prompted company advisors and safety…

Modular Medical Secures $4.4M Seeking to Fast-Track FDA Clearance and Launch Pivot Insulin Patch Pump -( $MODD $LLY $TNDM $MDT )

by John F. Heerdink, Jr. September 29, 2025 548Views 0Likes

Modular Medical (NASDAQ: MODD) has made a flurry of strategic moves and operational strides in recent weeks as it works to reshape the landscape of insulin delivery for millions living with diabetes. The company secured approximately $4.4 million in gross proceeds through…

Jennifer Garner’s Once Upon a Farm Files for NYSE IPO: Transforming Kids’ Nutrition with Farm-Fresh Values – ( $OFRM $GS $JPM $BAC )

by John F. Heerdink, Jr. September 29, 2025 729Views 0Likes

Once Upon a Farm, the organic baby and kids’ food pioneer co-founded by actress Jennifer Garner, officially filed for an initial public offering on the New York Stock Exchange this week, signaling a remarkable milestone for a brand that has fused celebrity…

Serina Therapeutics CEO: Why Now Is the Time to Invest in Biotech – ( $SER $IBB $XBI )

by John F. Heerdink, Jr. September 26, 2025 576Views 0Likes

In a video released this week, Serina Therapeutics' (NYSE American: SER) Chief Executive Officer Steven Ledger outlined what he described as a rare convergence of factors for biotech investing, highlighting both daunting market conditions and an emerging window of opportunity. Watch Now…

Palsonify FDA Greenlight: Crinetics Seeks to Launch Oral Therapy for Acromegaly Patients – ( $CRNX $IBB $XBI )

by John F. Heerdink, Jr. September 26, 2025 531Views 0Likes

San Diego, CA based Crinetics Pharmaceuticals (CRNX) delivered a watershed moment on Friday as the FDA granted approval of Palsonify (paltusotine), the first once-daily, oral therapy for acromegaly—a rare hormonal disorder—propelling shares to their strongest session of the year. On Friday, Crinetics…

Cantor Fitzgerald Analyst Report Drives Biotech Buzz About Eupraxia After Major Funding – ( $EPRX $IBB $XBI )

by John F. Heerdink, Jr. September 25, 2025 500Views 0Likes

Cantor Fitzgerald has recently updated their coverage of Eupraxia Pharmaceuticals (NASDAQ: EPRX) with an “Overweight” rating and an $11 target price—a move that places the emerging biotech on the radar of institutional investors seeking innovation in the field of locally delivered, extended-release…

uniQure Stock Soars 196% on Huntington’s Disease Gene Therapy Potential Breakthrough – ( $QURE $IBB $XBI )

by John F. Heerdink, Jr. September 24, 2025 544Views 0Likes

uniQure (NASDAQ: QURE) electrified Wall Street this week, with shares surging nearly 200% after the company reportedly announced transformative clinical data for its Huntington’s disease gene therapy, AMT-130. The biotech, which just secured up to $175 million in non-dilutive funding, is riding…

Pfizer’s $4.9 Billion Metsera Deal Shakes Up GLP-1 Market: Modular Medical, Eli Lilly Advance Obesity Solutions – ( $PFE $MSTR $MODD $LLY $TNDM )

by John F. Heerdink, Jr. September 22, 2025 773Views 0Likes

Pfizer’s (PFE) move to acquire Metsera (Monday, Sept. 22, 2025) for up to $4.9 billion marks a pivotal expansion in the fast-evolving obesity and diabetes treatment market, intensifying the industry’s GLP-1 rivalry among major pharmaceutical players. Modular Medical (NASDAQ: MODD), with its…

U.S. Based GeoVax Labs Seeks To Challenge Bavarian Nordic’s Vaccine Monopoly Amid $3 Billion Buyout – ( $GOVX $BVNKF $IBB $XBI )

by John F. Heerdink, Jr. September 22, 2025 537Views 0Likes

GeoVax Labs, Inc. (NASDAQ: GOVX), an American clinical-stage biotechnology company, is advancing its Modified Vaccinia Ankara (MVA) vaccine platform, positioning itself as a key domestic alternative to Europe's Bavarian Nordic in addressing critical global health threats such as Mpox and smallpox. This…

Market News

Your Guide To Staying Informed In The Markets